Navigation Links
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
Date:12/20/2013

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

(Logo:  http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )

The research program is focused on the super-benzopyran drug, Trilexium (Trx).

The brain cancer program parallels that of the Company's efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both ovarian cancer stem cells and ovarian cancer somatic cells, raising the prospect for the first time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer. The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this technology platform.

The brain cancer program has the same R&D and commercial objectives. The near-term goal is to bring Trilexium into the clinic as a generic treatment for GBM that has failed to respond to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel of drugs capable of providing a personalized approach to GBM chemo
'/>"/>

SOURCE Novogen Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
2. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
3. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
4. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
5. Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
6. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
7. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
8. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by type (Empty, ... by Application [GC, LC (HPLC, UHPLC, Flash Chromatography, ... and studies the major market drivers, restraints, opportunities, ... Rest of the World. , Browse 90 market ... pages and in-depth TOC on “Chiral Chromatography Columns ...
(Date:11/22/2014)... , November 21, 2014   ... als Chief Commercial Officer zu KLOX    ... Unternehmensentwicklung und Chief Financial Officer bestellt    ... der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu ... bzw. das "Unternehmen") ist sehr erfreut, die folgenden personellen ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
Breaking Biology Technology:Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... Co., Ltd., and its parent company, Otsuka Holdings Co., ... for Human Use (CHMP), a division of the European ... of Teysuno™ (S-1), a novel oral anti-cancer agent, intended ... when given in combination with cisplatin. The Committee will ...
... Catal de Nanotecnologia (ICN), in Barcelona, has demonstrated a device ... key step in developing the spin computers of the future. ... the journal Science. The authors are Marius V. Costache and ... the Physics and Engineering of Nanodevices Group at ICN. ...
... Quest Diagnostics (NYSE: DGX ), the ... services, today announced that its Care360™ Electronic Health ... was certified as a Complete EHR on Wednesday, ... eligible Health Information Technology (CCHIT®), an ONC-ATCB, in ...
Cached Biology Technology:Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 2Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 3Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 4A 'spin ratchet': A new electronic structure for generating spin current 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 3Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 4
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/15/2014)... we may still be a few years away from the ... gain instant access to all that ailed his patients, mobile ... for monitoring and measuring our health are cropping up in ... tad Orwellian to some, but a new survey suggests that ... into their healthcare regime. These are some of ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... at the University of North Carolina at Chapel Hill have ... programmed cell death or apoptosis. This molecule, a tiny ... shown to be in short supply in certain neurodegenerative illnesses ... could herald a new treatment to prompt brain cells to ...
... lower total and LDL (low-density lipoprotein or "the ... mechanism whereby soy protein lowers cholesterol remains unresolved. ... of Clinical Lipidology last month shows that ... lipoprotein) cholesterol significantly more than milk protein in ...
... even though their close relatives rays and chimaeras have ... Nathan Scott Hart and colleagues from the University of ... Their study shows that although the eyes of sharks ... only have a single long-wavelength-sensitive cone* type in the ...
Cached Biology News:New molecule could save brain cells from neurodegeneration, stroke 2New molecule could save brain cells from neurodegeneration, stroke 3New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein 2Are sharks color blind? 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: